Alnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) will be posting its quarterly earnings results before the market opens on Thursday, February 15th. Analysts expect Alnylam Pharmaceuticals to post earnings of ($1.19) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Alnylam Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:ALNY opened at $169.34 on Tuesday. The company’s fifty day moving average is $183.67 and its two-hundred day moving average is $179.31. Alnylam Pharmaceuticals has a 12-month low of $148.10 and a 12-month high of $227.91. The company has a market cap of $21.25 billion, a P/E ratio of -40.90 and a beta of 0.43.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Michael W. Bonney sold 30,000 shares of the stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $195.00, for a total value of $5,850,000.00. Following the transaction, the director now owns 16,029 shares of the company’s stock, valued at approximately $3,125,655. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp boosted its position in shares of Alnylam Pharmaceuticals by 44.5% in the 4th quarter. Stifel Financial Corp now owns 11,658 shares of the biopharmaceutical company’s stock worth $2,232,000 after purchasing an additional 3,589 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Alnylam Pharmaceuticals by 14.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 480 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 60 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $360,000. Comerica Bank bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $2,377,000. Finally, Advisors Asset Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 40.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,292 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 375 shares during the last quarter. 93.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Piper Sandler boosted their target price on shares of Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an “overweight” rating in a research note on Thursday, December 14th. Wells Fargo & Company started coverage on shares of Alnylam Pharmaceuticals in a research note on Friday, December 8th. They issued an “equal weight” rating and a $171.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $395.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, December 15th. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $235.00 to $230.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $230.95.

Check Out Our Latest Analysis on Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Stories

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.